FDA — authorised 7 December 1959
- Application: NDA012164
- Marketing authorisation holder: APOTHECON
- Local brand name: NATURETIN-2.5
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Corzide in United States
FDA authorised Corzide on 7 December 1959
Marketing authorisations
FDA — authorised 25 May 1983
- Application: NDA018647
- Marketing authorisation holder: KING PHARMS LLC
- Local brand name: CORZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 March 2007
- Application: ANDA077833
- Marketing authorisation holder: IMPAX LABS
- Local brand name: NADOLOL AND BENDROFLUMETHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 15 February 2008
- Application: ANDA078688
- Marketing authorisation holder: NATCO PHARMA
- Local brand name: NADOLOL AND BENDROFLUMETHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Status: approved
Corzide in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Cardiovascular approved in United States
Frequently asked questions
Is Corzide approved in United States?
Yes. FDA authorised it on 7 December 1959; FDA authorised it on 25 May 1983; FDA authorised it on 30 March 2007.
Who is the marketing authorisation holder for Corzide in United States?
APOTHECON holds the US marketing authorisation.